Related content

Patient-Specific Dose Adjustment in the Cancer Clinical Trial Setting

By Rogatko André   Ghosh Pulak   Vidakovic Brani   Tighiouart Mourad  

Pharmaceutical Medicine, Vol. 22, Iss. 6, 2008-01 ,pp. : 345-350

Adis International

Access to resources Recommend Favorite

Methods to Analyse Cost Data of Patients Who Withdraw in a Clinical Trial Setting

By Oostenbrink J.B.   Al M.J.   Mölken M.P.M.H.R-v.  

PharmacoEconomics, Vol. 21, Iss. 15, 2003-01 ,pp. : 1103-1112

Adis International

Access to resources Recommend Favorite

A Randomised Trial of the Cost Effectiveness of Buprenorphine as an Alternative to Methadone Maintenance Treatment for Heroin Dependence in a Primary Care Setting

By Anthony H. Harris  

PharmacoEconomics, Vol. 23, Iss. 1, 2005-01 ,pp. : 77-91

Adis International

Access to resources Recommend Favorite

Cardioprotection in the Clinical Setting

By Ivanes Fabrice   Mewton Nathan   Rioufol Gilles   Piot Christophe   Elbaz Meyer   Revel Didier   Croisille Pierre   Ovize Michel  

Cardiovascular Drugs and Therapy, Vol. 24, Iss. 3, 2010-06 ,pp. : 281-287

Springer Publishing Company

Access to resources Recommend Favorite

A placebo-controlled, double-blind, randomised trial of magnesium-pyridoxal-5'-phosphate-glutamate for hypercholesterolaemia and other clinical–chemical risk factors of cardiovascular disease in a primary care setting

By Schuitemaker G.E.   van der Pol G.A.   Aretz C.P.M.   Dinant G.J.  

European Journal of Clinical Pharmacology, Vol. 56, Iss. 12, 2001-03 ,pp. : 857-863

Springer Publishing Company

Access to resources Recommend Favorite